Bio Micro-Nano Technologies of Antioxidants Optimised Their Pharmacological and Cellular Effects, ex vivo, in Pancreatic β-Cells

References

• LaVeist TA, Thorpe RJ Jr., Galarraga JE, Bower KM, Gary-Webb TL. Environmental and socio-economic factors as contributors to racial disparities in diabetes prevalence. J Gen Intern Med. 2009;24(10):1144–1148. doi:10.1007/s11606-009-1085-719685264
   PubMed Web of Science ®Google Scholar
• Chittleborough CR, Grant JF, Phillips PJ, Taylor AW. The increasing prevalence of diabetes in South Australia: the relationship with population ageing and obesity. Public Health. 2007;121(2):92–99. doi:10.1016/j.puhe.2006.09.01717166533
   PubMed Web of Science ®Google Scholar
• King H, Dixon J, Senator G, Zimmet P. Insulin-treated diabetes in Tasmania: population-based clinical characteristics and their possible implications for diabetic health care in Australia. Med J Aust. 1989;151(8):444, 446, 448, 450. doi:10.5694/j.1326-5377.1989.tb101254.x2687669
   PubMed Web of Science ®Google Scholar
• D’Antonio JA, Ellis D, Doft BH, et al. Diabetes complications and glycemic control. The Pittsburgh prospective insulin-dependent diabetes cohort study status report after 5 yr of IDDM. Diabetes Care. 1989;12(10):694–700. doi:10.2337/diacare.12.10.6942612304
   PubMed Web of Science ®Google Scholar
• Harris TJ, Cook DG, Wicks PD, Cappuccio FP. Impact of the new American Diabetes Association and World Health Organisation diagnostic criteria for diabetes on subjects from three ethnic groups living in the UK. Nutr Metab Cardiovasc Dis. 2000;10(6):305–309.11302004
   PubMed Web of Science ®Google Scholar
• Alberti KG. The World Health Organisation and diabetes. Diabetologia. 1980;19(3):169–173. doi:10.1007/BF002752647409363
   PubMed Web of Science ®Google Scholar
• Polenova NV, Vaulin NA, Masenko VP, Iavelov IS, Gratsianskii NA. [Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation]. Kardiologiia. 2009;49(2):9–14.
   Web of Science ®Google Scholar
• Szpigel A, Hainault I, Carlier A, et al. Lipid environment induces ER stress, TXNIP expression and inflammation in immune cells of individuals with type 2 diabetes. Diabetologia. 2017;61(2):399–412.28988346
   PubMed Web of Science ®Google Scholar
• de Souza Bastos A, Graves DT, de Melo Loureiro AP, et al. Diabetes and increased lipid peroxidation are associated with systemic inflammation even in well-controlled patients. J Diabetes Complications. 2016;30(8):1593–1599. doi:10.1016/j.jdiacomp.2016.07.01127497685
   PubMed Web of Science ®Google Scholar
• Ha CY, Kim JY, Paik JK, et al. The association of specific metabolites of lipid metabolism with markers of oxidative stress, inflammation and arterial stiffness in men with newly diagnosed type 2 diabetes. Clin Endocrinol (Oxf). 2012;76(5):674–682. doi:10.1111/cen.2012.76.issue-521958081
   PubMed Web of Science ®Google Scholar
• Kubo Y, Terashima Y, Yagi N, Nochi H, Tamoto K, Sekikawa H. Enhanced bioavailability of probucol following the administration of solid dispersion systems of probucol-polyvinylpyrrolidone in rabbits. Biol Pharm Bull. 2009;32(11):1880–1884. doi:10.1248/bpb.32.188019881302
   PubMed Web of Science ®Google Scholar
• Rinninger F, Wang N, Ramakrishnan R, Jiang XC, Tall AR. Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism. Arterioscler Thromb Vasc Biol. 1999;19(5):1325–1332. doi:10.1161/01.ATV.19.5.132510323786
   PubMed Web of Science ®Google Scholar
• Ma Q, Han Y, Chen C, et al. Oral absorption enhancement of probucol by PEGylated G5 PAMAM dendrimer modified nanoliposomes. Mol Pharm. 2015;12(3):665–674. doi:10.1021/mp500388m25587935
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Chen-Tan N, et al. Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Des Devel Ther. 2014;8:1221–1230. doi:10.2147/DDDT.S67349
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Al-Sallami HS, et al. Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes. AAPS PharmSciTech. 2015;16(1):45–52. doi:10.1208/s12249-014-0205-925168450
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Arfuso F, Al-Salami H. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study. Drug Deliv Transl Res. 2015;5(5):511–522. doi:10.1007/s13346-015-0248-926242686
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Arfuso F, Al-Salami H. Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: formulation characterization and effects on production of insulin and inflammation in a pancreatic beta-cell line. Artif Cells Nanomed Biotechnol. 2016;44(7):1642–1653. doi:10.3109/21691401.2015.106929926377035
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Chen-Tan N, Watts GF, Arfuso F, Al-Salami H. An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer. Drug Des Devel Ther. 2014;8:1673–1683. doi:10.2147/DDDT.S68247
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Al-Sallami HS, et al. Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment. J Microencapsul. 2015;32(2):151–156. doi:10.3109/02652048.2014.95820425265061
   PubMed Web of Science ®Google Scholar
• Negrulj R, Mooranian A, Chen-Tan N, et al. Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes. Artif Cells Nanomed Biotechnol. 2016;44(5):1290–1297. doi:10.3109/21691401.2015.102484525811999
   PubMed Web of Science ®Google Scholar
• Cetin M, Atila A, Sahin S, Vural I. Preparation and characterization of metformin hydrochloride loaded-Eudragit® RSPO and Eudragit® RSPO/PLGA nanoparticles. Pharm Dev Technol. 2013;18(3):570–576. doi:10.3109/10837450.2011.60478321864098
   PubMed Web of Science ®Google Scholar
• Enose Appavoo A, Anand P, Bhaskar K, Ramachandran S, Saravanan M, Vinod R. Eudragit NE30D based metformin/gliclazide extended release tablets: formulation, characterisation and in vitro release studies. Notes. 2002;50(11):1495–1498.
   Google Scholar
• Devarajan PV, Sonavane GS. Preparation and in vitro/in vivo evaluation of gliclazide loaded Eudragit nanoparticles as a sustained release carriers. Drug Dev Ind Pharm. 2007;33(2):101–111. doi:10.1080/0363904060109669517454041
   PubMed Web of Science ®Google Scholar
• Arno EA, Anand P, Bhaskar K, Ramachandran S, Saravanan M, Vinod R. Eudragit NE30D based metformin/gliclazide extended release tablets: formulation, characterisation and in vitro release studies. Chem Pharm Bull (Tokyo). 2002;50(11):1495–1498. doi:10.1248/cpb.50.149512419917
   PubMed Web of Science ®Google Scholar
• Mooranian A, Tackechi R, Jamieson E, Morahan G, Al-Salami H. Innovative microcapsules for pancreatic beta-cells harvested from mature double-transgenic mice: cell imaging, viability, induced glucose-stimulated insulin measurements and proinflammatory cytokines analysis. Pharm Res. 2017;34(6):1217–1223. doi:10.1007/s11095-017-2138-y28289997
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Takechi R, Jamieson E, Morahan G, Al-Salami H. Electrokinetic potential-stabilization by bile acid-microencapsulating formulation of pancreatic beta-cells cultured in high ratio poly-L-ornithine-gel hydrogel colloidal dispersion: applications in cell-biomaterials, tissue engineering and biotechnological applications. Artif Cells Nanomed Biotechnol. 2018;46(6):1156–1162.28776395
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Mathavan S, et al. Stability and release kinetics of an advanced gliclazide-cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics. J Pharm Innov. 2014;9(2):150–157. doi:10.1007/s12247-014-9182-524829616
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Mathavan S, et al. An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharm Dev Technol. 2015;20;6:702–709.24798888
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Arfuso F, Al-Salami H. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study. Drug Deliv Transl Res. 2015;5:1–12.25787334
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Mikov M, Golocorbin-Kon S, Arfuso F, Al-Salami H. Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro Study. J Microencapsulation. 2015;32:1–9.
   Web of Science ®Google Scholar
• Negrulj R, Mooranian A, Chen-Tan N, et al. Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes. Artif Cells Nanomed Biotechnol. 2015;44:1290–1297.25811999
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Al-Sallami HS, et al. Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment. J Microencapsul. 2014;32:1–6.25265057
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Mathavan S, et al. Stability and release kinetics of an advanced gliclazide-cholic acid formulation: the use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabetics. J Pharm Innov. 2014;9:1–8.
   Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Al-Sallami HS, et al. Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes. AAPS PharmSciTech. 2014;16:45–52.25168450
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Takechi R, Mamo JC, Al-Sallami H, Al-Salami H. The biological effects of the hypolipidaemic drug probucol incorporated into bile acid-microcapsules and fed daily for 4-weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects. Drug Deliv Transl Res. 2018;8:543–551. doi:10.1007/s13346-017-0473-529313296
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Jamieson E, Morahan G, Al-Salami H. Biological assessments of encapsulated pancreatic β-cells: their potential transplantation in diabetes. Cell Mol Bioeng. 2017;9:530–537.
   Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Chen-Tan N, et al. Advanced bile acid-based multi-compartmental microencapsulated pancreatic beta-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment. Artif Cells Nanomed Biotechnol. 2016;44(2):588–595. doi:10.3109/21691401.2014.97180625358121
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Arfuso F, Al-Salami H. Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic beta-cells. Artif Cells Nanomed Biotechnol. 2016;44(1):194–200. doi:10.3109/21691401.2014.93445725014218
   PubMed Web of Science ®Google Scholar
• Chang SJ, Lee CH, Hsu CY, Wang YJ. Biocompatible microcapsules with enhanced mechanical strength. J Biomed Mater Res. 2002;59(1):118–126. doi:10.1002/(ISSN)1097-463611745544
   PubMed Web of Science ®Google Scholar
• Sun G, Zhang Z. Mechanical strength of microcapsules made of different wall materials. Int J Pharm. 2002;242(1–2):307–311. doi:10.1016/S0378-5173(02)00193-X12176269
   PubMed Web of Science ®Google Scholar
• Okonogi S, Oguchi T, Yonemochi E, Puttipipatkhachorn S, Yamamoto K. Physicochemical properties of ursodeoxycholic acid dispersed in controlled pore glass. J Colloid Interface Sci. 1999;216(2):276–284. doi:10.1006/jcis.1999.633110421735
   PubMed Web of Science ®Google Scholar
• Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest. 1998;101(12):2790–2799. doi:10.1172/JCI13259637713
   PubMed Web of Science ®Google Scholar
• Rodrigues C, Fan G, Wong PY, Kren BT, Steer CJ. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med. 1998;4(3):165. doi:10.1007/BF034019149562975
   PubMed Web of Science ®Google Scholar
• Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J. 2006;25(7):1419–1425. doi:10.1038/sj.emboj.760104916541101
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Arfuso F, Al-Salami H. Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic β-cells. Artif Nanomed Biotechnol. 2016;44(1):194–200. doi:10.3109/21691401.2014.934457
   PubMed Web of Science ®Google Scholar
• Mooranian A, Negrulj R, Al-Salami H. The incorporation of water-soluble gel matrix into bile acid-based microcapsules for the delivery of viable β-cells of the pancreas, in diabetes treatment: biocompatibility and functionality studies. Drug Deliv Transl Res. 2016;6(1):17–23. doi:10.1007/s13346-015-0268-526671765
   PubMed Web of Science ®Google Scholar
• Mooranian A, Zamani N, Takechi R, et al. Pharmacological Effects of Nanoencapsulation of Human-Based Dosing of Probucol on Ratio of Secondary to Primary Bile Acids in Gut, During Induction and Progression of Type 1 Diabetes. Artif Cells Nanomed Biotechnol. 2018;46(sup3):S748-S754.
   Google Scholar